EYPT
- EyePoint Pharmaceuticals, Inc.
()
Overview
Company Summary
EyePoint Pharmaceuticals, Inc. is a specialty pharmaceutical company that focuses on the development and commercialization of innovative ophthalmic products. They primarily specialize in sustained-release drug delivery systems designed to improve the efficacy and convenience of ocular treatments.
EyePoint Pharmaceuticals utilizes their proprietary technology platforms, such as Durasert and Verisome, to develop and deliver drugs to specific areas of the eye over an extended period of time. These sustained-release platforms aim to provide patients with more convenient treatment options, reducing the frequency of administration of medications and potentially improving patient compliance.
The company's product portfolio includes both commercialized and investigational pharmaceuticals. Iluvien, their lead product, is approved by regulatory authorities in the United States and Europe for the treatment of diabetic macular edema (DME), a leading cause of vision loss in diabetic patients. Iluvien is an intravitreal implant that releases a corticosteroid, providing continuous and controlled drug delivery for up to 36 months.
Additionally, EyePoint Pharmaceuticals is actively working on developing other sustained-release ocular therapies for conditions such as uveitis, wet and dry age-related macular degeneration, and glaucoma. These products are currently in various stages of clinical development and may provide additional treatment options for patients in the future.
Overall, EyePoint Pharmaceuticals focuses on leveraging its innovative sustained-release technology to address unmet medical needs in the ophthalmic field, offering treatments that can improve outcomes, reduce treatment burden, and enhance the quality of life for patients with various eye diseases.